44 results on '"Lifschytz T"'
Search Results
2. CDH2 mutation affecting N-cadherin function causes attention-deficit hyperactivity disorder in humans and mice
- Author
-
Halperin, D., Stavsky, A., Kadir, R., Drabkin, M., Wormser, O., Yogev, Y., Dolgin, V., Proskorovski-Ohayon, R., Perez, Y., Nudelman, H., Stoler, O., Rotblat, B., Lifschytz, T., Lotan, A., Meiri, G., Gitler, D., and Birk, O. S.
- Published
- 2021
- Full Text
- View/download PDF
3. Therapeutic mechanism of psilocybin in the treatment of depression and other psychiatric disorders.
- Author
-
Shahar, O., primary, Botvinik, A., additional, Lifschytz, T., additional, and Lerer, B., additional
- Published
- 2023
- Full Text
- View/download PDF
4. Alterations in the expression of a neurodevelopmental gene exert long-lasting effects on cognitive-emotional phenotypes and functional brain networks: translational evidence from the stress-resilient Ahi1 knockout mouse
- Author
-
Lotan, A, Lifschytz, T, Mernick, B, Lory, O, Levi, E, Ben-Shimol, E, Goelman, G, and Lerer, B
- Published
- 2016
- Full Text
- View/download PDF
5. Neural mechanisms underlying stress resilience in Ahi1 knockout mice: relevance to neuropsychiatric disorders
- Author
-
Lotan, A, Lifschytz, T, Slonimsky, A, Broner, E C, Greenbaum, L, Abedat, S, Fellig, Y, Cohen, H, Lory, O, Goelman, G, and Lerer, B
- Published
- 2014
- Full Text
- View/download PDF
6. Amygdalar disconnectivity could underlie stress resilience in the Ahi1 knockout mouse: conclusions from a resting-state functional MRI study
- Author
-
Lotan, A, Lifschytz, T, Lory, O, Goelman, G, and Lerer, B
- Published
- 2014
- Full Text
- View/download PDF
7. Differential effects of chronic stress in young-adult and old female mice: cognitive-behavioral manifestations and neurobiological correlates
- Author
-
Lotan, A, primary, Lifschytz, T, additional, Wolf, G, additional, Keller, S, additional, Ben-Ari, H, additional, Tatarsky, P, additional, Pillar, N, additional, Oved, K, additional, Sharabany, J, additional, Merzel, T K, additional, Matsumoto, T, additional, Yamawaki, Y, additional, Mernick, B, additional, Avidan, E, additional, Yamawaki, S, additional, Weller, A, additional, Shomron, N, additional, and Lerer, B, additional
- Published
- 2017
- Full Text
- View/download PDF
8. P.2.017 Differential effect of chronic stress on cognition and affect in young and old mice
- Author
-
Tatarskyy, P., primary, Lotan, A., additional, Lifschytz, T., additional, Mernick, B., additional, Wolf, G., additional, Ben-Ari, H., additional, and Lerer, B., additional
- Published
- 2016
- Full Text
- View/download PDF
9. Na +, k +-ATPase and endogenous cardiac steroids in depressive disorders
- Author
-
Lichtstein, D., Hodes, A., Goldstein, I., Rosen, H., Ovadia, H., and Lifschytz, T.
- Abstract
Depressive disorders, including major depression, dysthymia and bipolar disorder (BD), are a serious and devastating group of diseases that have a major impact on the patient’s quality of life. The etiology of depressive disorders remains unclear. It is now recognized that the Monoaminergic hypothesis for the etiology of depressive disorders, which dominated the field for decades, cannot by itself explain the complex etiology of these diseases. Endogenous cardiac steroids (CS) are present in the circulation and in the brain and are considered as hormones synthesized in and released from the adrenal gland. The binding of CS to Na +, K +-ATPase inhibits the transport of these ions and leads to the activation of several cell-specific signaling pathways. Recent studies from our and other laboratories have shown that: (1) CS levels in the parietal cortex of BD patients are significantly higher and those in the plasma are lower than in normal subjects; (2) Intra-cerebro-ventricle (i.c.v) injection of anti-ouabain antibodies, which lower brain endogenous CS levels, into Sprague Dawley (SD) rats elicited anti-depressive and anti-manic behaviors in Forced Swimming Test, and amphetamine-induced hyperactivity, respectively; (3) A significant association with BD was observed for six single-nucleotide polymorphisms (SNPs) in the three genes encoding the Na, K-ATPase α isoforms and for a specific polymorphism within the gene encoding the α3 isoform; (4) Acute i.c.v. injection of anti-ouabain antibodies into SD rats caused significant changes in catecholamine levels in brain areas associated with depression; and (5) Injection of a 4-(3''α-15''β-dihydroxy-5''β-estran-17''β-yl) furan-2-methyl alcohol, an antagonistic to CS in several experimental systems, induced an anti-depressive response in SD rats. These results are in accordance with the notion that malfunctioning of the Na +, K +-ATPase/CS system may be involved in the manifestation of depressive disorders and BD in particular and identify the system as a target for the treatment of these maladies.
- Published
- 2013
10. Differential effects of chronic stress in young-adult and old female mice: cognitive-behavioral manifestations and neurobiological correlates
- Author
-
Lotan, A, Lifschytz, T, Wolf, G, Keller, S, Ben-Ari, H, Tatarsky, P, Pillar, N, Oved, K, Sharabany, J, Merzel, T K, Matsumoto, T, Yamawaki, Y, Mernick, B, Avidan, E, Yamawaki, S, Weller, A, Shomron, N, and Lerer, B
- Abstract
Stress-related psychopathology is highly prevalent among elderly individuals and is associated with detrimental effects on mood, appetite and cognition. Conversely, under certain circumstances repeated mild-to-moderate stressors have been shown to enhance cognitive performance in rodents and exert stress-inoculating effects in humans. As most stress-related favorable outcomes have been reported in adolescence and young-adulthood, this apparent disparity could result from fundamental differences in how aging organisms respond to stress. Furthermore, given prominent age-related alterations in sex hormones, the effect of chronic stress in aging females remains a highly relevant yet little studied issue. In the present study, female C57BL/6 mice aged 3 (young-adult) and 20–23 (old) months were subjected to 8 weeks of chronic unpredictable stress (CUS). Behavioral outcomes were measured during the last 3 weeks of the CUS protocol, followed by brain dissection for histological and molecular end points. We found that in young-adult female mice, CUS resulted in decreased anxiety-like behavior and enhanced cognitive performance, whereas in old female mice it led to weight loss, dysregulated locomotion and memory impairment. These phenotypes were paralleled by differential changes in the expression of hypothalamic insulin and melanocortin-4 receptors and were consistent with an age-dependent reduction in the dynamic range of stress-related changes in the hippocampal transcriptome. Supported by an integrated microRNA (miRNA)–mRNA expression analysis, the present study proposes that, when confronted with ongoing stress, neuroprotective mechanisms involving the upregulation of neurogenesis, Wnt signaling and miR-375 can be harnessed more effectively during young-adulthood. Conversely, we suggest that aging alters the pattern of immune activation elicited by stress. Ultimately, interventions that modulate these processes could reduce the burden of stress-related psychopathology in late life.
- Published
- 2018
- Full Text
- View/download PDF
11. P.1.018 Dissecting the neural mechanisms underlying impaired threat detection in the Ahi1 knockout mouse
- Author
-
Lotan, A., primary, Lifschytz, T., additional, Slonimsky, A., additional, Abedat, S., additional, Fellig, Y., additional, Cohen, H., additional, Lory, O., additional, Goelman, G., additional, and Lerer, B., additional
- Published
- 2013
- Full Text
- View/download PDF
12. Alterations in the expression of a neurodevelopmental gene exert long-lasting effects on cognitive-emotional phenotypes and functional brain networks: translational evidence from the stress-resilient Ahi1 knockout mouse
- Author
-
Lotan, A, Lifschytz, T, Mernick, B, Lory, O, Levi, E, Ben-Shimol, E, Goelman, G, and Lerer, B
- Abstract
Many psychiatric disorders are highly heritable and may represent the clinical outcome of early aberrations in the formation of neural networks. The placement of brain connectivity as an ‘intermediate phenotype’ renders it an attractive target for exploring its interaction with genomics and behavior. Given the complexity of genetic make up and phenotypic heterogeneity in humans, translational studies are indicated. Recently, we demonstrated that a mouse model with heterozygous knockout of the key neurodevelopmental gene Ahi1 displays a consistent stress-resilient phenotype. Extending these data, the current research describes our multi-faceted effort to link early variations in Ahi1 expression with long-term consequences for functional brain networks and cognitive-emotional phenotypes. By combining behavioral paradigms with graph-based analysis of whole-brain functional networks, and then cross-validating the data with robust neuroinformatic data sets, our research suggests that physiological variation in gene expression during neurodevelopment is eventually translated into a continuum of global network metrics that serve as intermediate phenotypes. Within this framework, we suggest that organization of functional brain networks may result, in part, from an adaptive trade-off between efficiency and resilience, ultimately culminating in a phenotypic diversity that encompasses dimensions such as emotional regulation and cognitive function.
- Published
- 2017
- Full Text
- View/download PDF
13. Effect of Triiodothyronine on Antidepressant Screening Tests in Mice and on Presynaptic 5-HT1A Receptors: Mediation by Thyroid Hormone α Receptors
- Author
-
Lifschytz, T., primary, Zozulinsky, P., additional, Eitan, R., additional, Landshut, G., additional, Ohayon, S., additional, and Lerer, B., additional
- Published
- 2011
- Full Text
- View/download PDF
14. Treatment of major depression with thyroid hormone: Preclinical, clinical and genetic aspects
- Author
-
Lerer, B., primary, Cooper-Kazaz, R., additional, Lifschytz, T., additional, and Peeters, R., additional
- Published
- 2008
- Full Text
- View/download PDF
15. P.1.20 Mechanisms of the antidepressant action of triiodothyronine: functional, behavioral and gene expression studies
- Author
-
Lifschytz, T., primary, Shalom, G., additional, Goltser-Dubner, T., additional, Segman, R.H., additional, Lerer, B., additional, and Newman, M., additional
- Published
- 2008
- Full Text
- View/download PDF
16. Effects of T3 and fluoxetine in the novelty-suppressed feeding test model of depression and anxiety: gender differences
- Author
-
Shalom, G., Lifschytz, T., Lerer, B., and Newman, M.E.
- Published
- 2006
- Full Text
- View/download PDF
17. Strain related gender differences in cortical 5-HT autoreceptors response to sub-chronic fluoxetin.
- Author
-
Shalom, G., Lifschytz, T., Gur, E., Lerer, B., and Michael, N.
- Published
- 2005
18. Animal models for investigating the basis of the Thyroid hormon T3"s activity in the treatment of depression.
- Author
-
Lifschytz, T., Shalom, G., Lerer, B., Gur, E., and Newman, M. E.
- Published
- 2005
19. Striking long-term beneficial effects of single dose psilocybin and psychedelic mushroom extract in the SAPAP3 rodent model of OCD-like excessive self-grooming.
- Author
-
Brownstien M, Lazar M, Botvinnik A, Shevakh C, Blakolmer K, Lerer L, Lifschytz T, and Lerer B
- Abstract
Obsessive compulsive disorder (OCD) is a highly prevalent disorder that causes serious disability. Available treatments leave 40% or more of people with OCD significantly symptomatic. There is an urgent need for novel therapeutic approaches. Mice that carry a homozygous deletion of the SAPAP3 gene (SAPAP3 KO) manifest a phenotype of excessive self-grooming, tic-like head-body twitches and anxiety. These behaviors closely resemble pathological self-grooming behaviors observed in humans in conditions that overlap with OCD. Following a preliminary report that the tryptaminergic psychedelic, psilocybin, may reduce symptoms in patients with OCD, we undertook a randomized controlled trial of psilocybin in 50 SAPAP3 KO mice (28 male, 22 female). Mice that fulfilled inclusion criteria were randomly assigned to a single intraperitoneal injection of psilocybin (4.4 mg/kg), psychedelic mushroom extract (encompassing the same psilocybin dose) or vehicle control and were evaluated after 2, 12, and 21 days by a rater blind to treatment allocation for grooming characteristics, head-body twitches, anxiety, and other behavioral features. Mice treated with vehicle (n = 18) manifested a 118.71 ± 95.96% increase in total self-grooming (the primary outcome measure) over the 21-day observation period. In contrast, total self-grooming decreased by 14.60 ± 17.90% in mice treated with psilocybin (n = 16) and by 19.20 ± 20.05% in mice treated with psychedelic mushroom extract (n = 16) (p = 0.001 for effect of time; p = 0.0001 for time × treatment interaction). Five mice were dropped from the vehicle group because they developed skin lesions; 4 from the psilocybin group and none from the psychedelic mushroom extract group. Secondary outcome measures such as head-body twitches and anxiety all showed a significant improvement over 21 days. Notably, in mice that responded to psilocybin (n = 12) and psychedelic mushroom extract (n = 13), the beneficial effect of a single treatment persisted up to 7 weeks. Mice initially treated with vehicle and non-responsive, showed a clear and lasting therapeutic response when treated with a single dose of psilocybin or psychedelic mushroom extract and followed for a further 3 weeks. While equivalent to psilocybin in overall effect on self-grooming, psychedelic mushroom extract showed superior effects in alleviating head-body twitches and anxiety. These findings strongly justify clinical trials of psilocybin in the treatment of OCD and further studies aimed at elucidating mechanisms that underlie the long-term effects to alleviate excessive self-grooming observed in this study. Prepared with BioRender ( https://www.biorender.com/ )., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
20. Effect of chemically synthesized psilocybin and psychedelic mushroom extract on molecular and metabolic profiles in mouse brain.
- Author
-
Shahar O, Botvinnik A, Shwartz A, Lerer E, Golding P, Buko A, Hamid E, Kahn D, Guralnick M, Blakolmer K, Wolf G, Lotan A, Lerer L, Lerer B, and Lifschytz T
- Subjects
- Animals, Male, Mice, Agaricales metabolism, Neuronal Plasticity drug effects, Frontal Lobe metabolism, Frontal Lobe drug effects, Psilocybin pharmacology, Mice, Inbred C57BL, Brain metabolism, Brain drug effects, Hallucinogens pharmacology
- Abstract
Psilocybin, a naturally occurring, tryptamine alkaloid prodrug, is currently being investigated for the treatment of a range of psychiatric disorders. Preclinical reports suggest that the biological effects of psilocybin-containing mushroom extract or "full spectrum" (psychedelic) mushroom extract (PME), may differ from those of chemically synthesized psilocybin (PSIL). We compared the effects of PME to those of PSIL on the head twitch response (HTR), neuroplasticity-related synaptic proteins and frontal cortex metabolomic profiles in male C57Bl/6j mice. HTR measurement showed similar effects of PSIL and PME over 20 min. Brain specimens (frontal cortex, hippocampus, amygdala, striatum) were assayed for the synaptic proteins, GAP43, PSD95, synaptophysin and SV2A, using western blots. These proteins may serve as indicators of synaptic plasticity. Three days after treatment, there was minimal increase in synaptic proteins. After 11 days, PSIL and PME significantly increased GAP43 in the frontal cortex (p = 0.019; p = 0.039 respectively) and hippocampus (p = 0.015; p = 0.027) and synaptophysin in the hippocampus (p = 0.041; p = 0.05) and amygdala (p = 0.035; p = 0.004). PSIL increased SV2A in the amygdala (p = 0.036) and PME did so in the hippocampus (p = 0.014). In the striatum, synaptophysin was increased by PME only (p = 0.023). There were no significant effects of PSIL or PME on PSD95 in any brain area when these were analyzed separately. Nested analysis of variance (ANOVA) showed a significant increase in each of the 4 proteins over all brain areas for PME versus vehicle control, while significant PSIL effects were observed only in the hippocampus and amygdala and were limited to PSD95 and SV2A. Metabolomic analyses of the pre-frontal cortex were performed by untargeted polar metabolomics utilizing capillary electrophoresis - Fourier transform mass spectrometry (CE-FTMS) and showed a differential metabolic separation between PME and vehicle groups. The purines guanosine, hypoxanthine and inosine, associated with oxidative stress and energy production pathways, showed a progressive decline from VEH to PSIL to PME. In conclusion, our synaptic protein findings suggest that PME has a more potent and prolonged effect on synaptic plasticity than PSIL. Our metabolomics data support a gradient of effects from inert vehicle via chemical psilocybin to PME further supporting differential effects. Further studies are needed to confirm and extend these findings and to identify the molecules that may be responsible for the enhanced effects of PME as compared to psilocybin alone., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
21. Effects of psilocybin, psychedelic mushroom extract and 5-hydroxytryptophan on brain immediate early gene expression: Interaction with serotonergic receptor modulators.
- Author
-
Lerer E, Botvinnik A, Shahar O, Grad M, Blakolmer K, Shomron N, Lotan A, Lerer B, and Lifschytz T
- Abstract
Background: Immediate early genes (IEGs) are rapidly activated and initiate diverse cellular processes including neuroplasticity. We report the effect of psilocybin (PSIL), PSIL-containing psychedelic mushroom extract (PME) and 5-hydroxytryptophan (5-HTP) on expression of the IEGs, cfos, egr1 , and egr2 in mouse somatosensory cortex (SSC). Methods: In our initial experiment, male C57Bl/6j mice were injected with PSIL 4.4 mg/kg or 5-HTP 200 mg/kg, alone or immediately preceded by serotonergic receptor modulators. IEG mRNA expression 1 hour later was determined by real time qPCR. In a replication study a group of mice treated with PME was added. Results: In our initial experiment, PSIL but not 5-HTP significantly increased expression of all three IEGs. No correlation was observed between the head twitch response (HTR) induced by PSIL and its effect on the IEGs. The serotonergic receptor modulators did not significantly alter PSIL-induced IEG expression, with the exception of the 5-HT2C antagonist (RS102221), which significantly enhanced PSIL-induced egr2 expression. 5-HTP did not affect IEG expression. In our replication experiment, PSIL and PME upregulated levels of egr1 and cfos while the upregulation of egr2 was not significant. Conclusions: We have shown that PSIL and PME but not 5-HTP (at a dose sufficient to induce HTR), induced a significant increase in cfos and egr1 expression in mouse SSC. Our findings suggest that egr1 and cfos expression may be associated with psychedelic effects., Competing Interests: The study was supported in part by Parow Entheobiosciences. The funder had the following involvement in the study: KB was a scientific collaborator on the project., and as such, was involved in study design, collection, analysis, interpretation of data, the writing of this article, and the decision to submit it for publication. KB is an employee of Parow Entheobiosciences BL is a consultant to Parow Entheobiosciences. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2024 Lerer, Botvinnik, Shahar, Grad, Blakolmer, Shomron, Lotan, Lerer and Lifschytz.)
- Published
- 2024
- Full Text
- View/download PDF
22. Induced Muscle and Liver Absence of Gne in Postnatal Mice Does Not Result in Structural or Functional Muscle Impairment.
- Author
-
Harazi A, Yakovlev L, Ilouz N, Selke P, Horstkorte R, Fellig Y, Lahat O, Lifschytz T, Abudi N, Abramovitch R, Argov Z, and Mitrani-Rosenbaum S
- Subjects
- Animals, Mice, Distal Myopathies genetics, Distal Myopathies metabolism, Carbohydrate Epimerases genetics, Carbohydrate Epimerases metabolism, Multienzyme Complexes genetics, Multienzyme Complexes metabolism, N-Acetylneuraminic Acid metabolism, Muscle, Skeletal metabolism, Liver metabolism, Mice, Knockout, Disease Models, Animal
- Abstract
Background: GNE Myopathy is a unique recessive neuromuscular disorder characterized by adult-onset, slowly progressive distal and proximal muscle weakness, caused by mutations in the GNE gene which is a key enzyme in the biosynthesis of sialic acid. To date, the precise pathophysiology of the disease is not well understood and no reliable animal model is available. Gne KO is embryonically lethal in mice., Objective: To gain insights into GNE function in muscle, we have generated an inducible muscle Gne KO mouse. To minimize the contribution of the liver to the availability of sialic acid to muscle via the serum, we have also induced combined Gne KO in liver and muscle., Methods: A mouse carrying loxp sequences flanking Gne exon3 was generated by Crispr/Cas9 and bred with a human skeletal actin (HSA) promoter driven CreERT mouse. Gne muscle knock out was induced by tamoxifen injection of the resulting homozygote GneloxpEx3loxp/HSA Cre mouse. Liver Gne KO was induced by systemic injection of AAV8 vectors carrying the Cre gene driven by the hepatic specific promoter of the thyroxine binding globulin gene., Results: Characterization of these mice for a 12 months period showed no significant changes in their general behaviour, motor performance, muscle mass and structure in spite of a dramatic reduction in sialic acid content in both muscle and liver., Conclusions: We conclude that post weaning lack of Gne and sialic acid in muscle and liver have no pathologic effect in adult mice. These findings could reflect a strong interspecies versatility, but also raise questions about the loss of function hypothesis in Gne Myopathy. If these findings apply to humans they have a major impact on therapeutic strategies.
- Published
- 2024
- Full Text
- View/download PDF
23. Effect of psilocybin on marble burying in ICR mice: role of 5-HT1A receptors and implications for the treatment of obsessive-compulsive disorder.
- Author
-
Singh S, Botvinnik A, Shahar O, Wolf G, Yakobi C, Saban M, Salama A, Lotan A, Lerer B, and Lifschytz T
- Subjects
- Animals, Male, Mice, 8-Hydroxy-2-(di-n-propylamino)tetralin pharmacology, 8-Hydroxy-2-(di-n-propylamino)tetralin therapeutic use, Buspirone pharmacology, Buspirone therapeutic use, Escitalopram, Mice, Inbred ICR, Psilocybin pharmacology, Serotonin, Receptor, Serotonin, 5-HT1A, Hallucinogens pharmacology, Obsessive-Compulsive Disorder drug therapy
- Abstract
Preliminary clinical findings, supported by preclinical studies employing behavioral paradigms such as marble burying, suggest that psilocybin may be effective in treating obsessive-compulsive disorder. However, the receptor mechanisms implicated in the putative anti-obsessional effect are not clear. On this background, we set out to explore (1) the role of serotonin 2A (5-HT2A) and serotonin 1A (5-HT1A) receptors in the effect of psilocybin on marble burying; (2) the effect of staggered versus bolus psilocybin administration and persistence of the effect; (3) the effect of the 5-HT1A partial agonist, buspirone, on marble-burying and the head twitch response (HTR) induced by psilocybin, a rodent correlate of psychedelic effects. Male ICR mice were administered psilocybin 4.4 mg/kg, escitalopram 5 mg/kg, 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) 2 mg/kg, M100907 2 mg/kg, buspirone 5 mg/kg, WAY100635 2 mg/kg or combinations, intraperitoneally, and were tested on the marble burying test. HTR was examined in a magnetometer-based assay. The results show that (1) Psilocybin and escitalopram significantly reduced marble burying. The effect of psilocybin was not attenuated by the 5-HT2A antagonist, M100907. The 5-HT1A agonist, 8-OH-DPAT, reduced marble burying as did the 5-HT1A partial agonist, buspirone. The effect of 8-OH-DPAT was additive to that of psilocybin, but that of buspirone was not. The 5-HT1A antagonist, WAY100635, attenuated the effect of 8-OH-DPAT and buspirone but not the effect of psilocybin. (2) Psilocybin injections over 3.5 h had no effect on marble burying and the effect of bolus injection was not persistent. (3) Co-administration of buspirone with psilocybin blocked its effect on HTR. These data suggest that neither 5-HT2A nor 5-HT1A receptors are pivotally implicated in the effect of psilocybin on marble burying. Co-administration with buspirone may block the psychedelic effects of psilocybin without impeding its anti-obsessional effects., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
24. Correction: Targeting the DIO3 enzyme using first-in-class inhibitors effectively suppresses tumor growth: a new paradigm in ovarian cancer treatment.
- Author
-
Moskovich D, Finkelshtein Y, Alfandari A, Rosemarin A, Lifschytz T, Weisz A, Mondal S, Ungati H, Katzav A, Kidron D, Mugesh G, Ellis M, Lerer B, and Ashur-Fabian O
- Published
- 2023
- Full Text
- View/download PDF
25. Could psychedelic drugs have a role in the treatment of schizophrenia? Rationale and strategy for safe implementation.
- Author
-
Wolf G, Singh S, Blakolmer K, Lerer L, Lifschytz T, Heresco-Levy U, Lotan A, and Lerer B
- Subjects
- Animals, Humans, Hallucinogens therapeutic use, Hallucinogens pharmacology, Schizophrenia drug therapy, Psychotic Disorders drug therapy, Antipsychotic Agents therapeutic use
- Abstract
Schizophrenia is a widespread psychiatric disorder that affects 0.5-1.0% of the world's population and induces significant, long-term disability that exacts high personal and societal cost. Negative symptoms, which respond poorly to available antipsychotic drugs, are the primary cause of this disability. Association of negative symptoms with cortical atrophy and cell loss is widely reported. Psychedelic drugs are undergoing a significant renaissance in psychiatric disorders with efficacy reported in several conditions including depression, in individuals facing terminal cancer, posttraumatic stress disorder, and addiction. There is considerable evidence from preclinical studies and some support from human studies that psychedelics enhance neuroplasticity. In this Perspective, we consider the possibility that psychedelic drugs could have a role in treating cortical atrophy and cell loss in schizophrenia, and ameliorating the negative symptoms associated with these pathological manifestations. The foremost concern in treating schizophrenia patients with psychedelic drugs is induction or exacerbation of psychosis. We consider several strategies that could be implemented to mitigate the danger of psychotogenic effects and allow treatment of schizophrenia patients with psychedelics to be implemented. These include use of non-hallucinogenic derivatives, which are currently the focus of intense study, implementation of sub-psychedelic or microdosing, harnessing of entourage effects in extracts of psychedelic mushrooms, and blocking 5-HT2A receptor-mediated hallucinogenic effects. Preclinical studies that employ appropriate animal models are a prerequisite and clinical studies will need to be carefully designed on the basis of preclinical and translational data. Careful research in this area could significantly impact the treatment of one of the most severe and socially debilitating psychiatric disorders and open an exciting new frontier in psychopharmacology., (© 2022. The Author(s), under exclusive licence to Springer Nature Limited.)
- Published
- 2023
- Full Text
- View/download PDF
26. Role of 5-HT2A, 5-HT2C, 5-HT1A and TAAR1 Receptors in the Head Twitch Response Induced by 5-Hydroxytryptophan and Psilocybin: Translational Implications.
- Author
-
Shahar O, Botvinnik A, Esh-Zuntz N, Brownstien M, Wolf R, Lotan A, Wolf G, Lerer B, and Lifschytz T
- Subjects
- Mice, Humans, Animals, Male, Mice, Inbred C57BL, 5-Hydroxytryptophan pharmacology, Serotonin, Psilocybin pharmacology, Hallucinogens pharmacology
- Abstract
There is increasing interest in the therapeutic potential of psilocybin. In rodents, the serotonin precursor, 5-hydroxytryptophan (5-HTP) and psilocybin induce a characteristic 5-HT2A receptor (5-HT2AR)-mediated head twitch response (HTR), which is correlated with the human psychedelic trip. We examined the role of other serotonergic receptors and the trace amine -associated receptor 1 (TAAR1) in modulating 5-HTP- and psilocybin-induced HTR. Male C57BL/6J mice (11 weeks, ~30 g) were administered 5-HTP, 50-250 mg/kg i.p., 200 mg/kg i.p. after pretreatment with 5-HT/TAAR1 receptor modulators, psilocybin 0.1-25.6 mg/kg i.p. or 4.4 mg/kg i.p., immediately preceded by 5-HT/TAAR1 receptor modulators. HTR was assessed in a custom-built magnetometer. 5-HTP and psilocybin induced a dose-dependent increase in the frequency of HTR over 20 min with attenuation by the 5-HT2AR antagonist, M100907, and the 5-HT1AR agonist, 8-OH-DPAT. The 5-HT2CR antagonist, RS-102221, enhanced HTR at lower doses but reduced it at higher doses. The TAAR1 antagonist, EPPTB, reduced 5-HTP- but not psilocybin-induced HTR. We have confirmed the key role of 5-HT2AR in HTR, an inhibitory effect of 5-HT1AR, a bimodal contribution of 5-HT2CR and a role of TAAR1 in modulating HTR induced by 5-HTP. Compounds that modulate psychedelic-induced HTR have important potential in the emerging therapeutic use of these compounds.
- Published
- 2022
- Full Text
- View/download PDF
27. Targeting the DIO3 enzyme using first-in-class inhibitors effectively suppresses tumor growth: a new paradigm in ovarian cancer treatment.
- Author
-
Moskovich D, Finkelshtein Y, Alfandari A, Rosemarin A, Lifschytz T, Weisz A, Mondal S, Ungati H, Katzav A, Kidron D, Mugesh G, Ellis M, Lerer B, and Ashur-Fabian O
- Subjects
- Animals, Carcinoma, Ovarian Epithelial enzymology, Carcinoma, Ovarian Epithelial pathology, Cell Line, Tumor, Cell Proliferation drug effects, Cell Survival drug effects, Cystadenocarcinoma, Serous enzymology, Cystadenocarcinoma, Serous genetics, Cystadenocarcinoma, Serous pathology, Down-Regulation, Enzyme Inhibitors chemical synthesis, Enzyme Inhibitors pharmacology, Female, Gene Expression Regulation, Neoplastic drug effects, Gene Knockdown Techniques, Humans, Iodide Peroxidase antagonists & inhibitors, Iodide Peroxidase genetics, Mice, Molecular Mimicry, Small Molecule Libraries chemical synthesis, Small Molecule Libraries pharmacology, Xenograft Model Antitumor Assays, Carcinoma, Ovarian Epithelial drug therapy, Cystadenocarcinoma, Serous drug therapy, Enzyme Inhibitors administration & dosage, Iodide Peroxidase metabolism, Small Molecule Libraries administration & dosage
- Abstract
The enzyme iodothyronine deiodinase type 3 (DIO3) contributes to cancer proliferation by inactivating the tumor-suppressive actions of thyroid hormone (T3). We recently established DIO3 involvement in the progression of high-grade serous ovarian cancer (HGSOC). Here we provide a link between high DIO3 expression and lower survival in patients, similar to common disease markers such as Ki67, PAX8, CA-125, and CCNE1. These observations suggest that DIO3 is a logical target for inhibition. Using a DIO3 mimic, we developed original DIO3 inhibitors that contain a core of dibromomaleic anhydride (DBRMD) as scaffold. Two compounds, PBENZ-DBRMD and ITYR-DBRMD, demonstrated attenuated cell counts, induction in apoptosis, and a reduction in cell proliferation in DIO3-positive HGSOC cells (OVCAR3 and KURAMOCHI), but not in DIO3-negative normal ovary cells (CHOK1) and OVCAR3 depleted for DIO3 or its substrate, T3. Potent tumor inhibition with a high safety profile was further established in HGSOC xenograft model, with no effect in DIO3-depleted tumors. The antitumor effects are mediated by downregulation in an array of pro-cancerous proteins, the majority of which known to be repressed by T3. To conclude, using small molecules that specifically target the DIO3 enzyme we present a new treatment paradigm for ovarian cancer and potentially other DIO3-dependent malignancies., (© 2021. The Author(s), under exclusive licence to Springer Nature Limited.)
- Published
- 2021
- Full Text
- View/download PDF
28. White matter lesions, cerebral inflammation and cognitive function in a mouse model of cerebral hypoperfusion.
- Author
-
Ben-Ari H, Lifschytz T, Wolf G, Rigbi A, Blumenfeld-Katzir T, Merzel TK, Koroukhov N, Lotan A, and Lerer B
- Subjects
- Animals, Brain pathology, Carotid Artery, Common pathology, Carotid Stenosis physiopathology, Cerebrovascular Circulation, Cognition Disorders pathology, Cognitive Dysfunction pathology, Corpus Callosum pathology, Diffusion Tensor Imaging, Disease Models, Animal, Inflammation pathology, Learning physiology, Male, Memory Disorders pathology, Mice, Mice, Inbred C57BL, Microglia pathology, Cognition physiology, Dementia, Vascular pathology, White Matter pathology
- Abstract
Development of specific treatments for vascular dementia requires appropriate animal models. Bilateral carotid artery stenosis (BCAS) employs metal coils wrapped around both common carotid arteries to induce cerebral hypoperfusion, white matter lesions and memory impairment in mice. We focused on the relationship of memory impairment induced by BCAS to white matter lesions demonstrated by ex vivo magnetic resonance imaging (MRI). We found a significant effect of BCAS on perceptual learning in the novel object recognition test and on number of errors and latency to platform in the radial arm water maze. MRI analysis revealed a significant effect of BCAS on diffusion tensor imaging (DTI) parameters in white matter areas. After correction for multiple testing, significantly lower fractional anisotropy (FA) values were found in the corpus callosum and anterior commissure and significantly higher mean diffusivity values in the internal capsule. Focusing on the corpus callosum, we found that correlations between FA and number of errors on the RAWM test were significant after controlling for treatment. We further found that the effects of BCAS on cognition were partly mediated by its effects on white matter integrity. Immunofluorescence studies demonstrated significantly higher microglia cell density and soma size in the corpus callosum of BCAS mice compared to controls, and these parameters were correlated with the imaging data. The results of this study indicate that cognitive deficits induced by cerebral hypoperfusion due to BCAS result in part from microglia activation and disruption of white matter integrity, supporting the face and construct validity of this unique model of vascular dementia., (Copyright © 2019 Elsevier B.V. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
29. Effect of chronic unpredictable stress on mice with developmental under-expression of the Ahi1 gene: behavioral manifestations and neurobiological correlates.
- Author
-
Wolf G, Lifschytz T, Ben-Ari H, Tatarskyy P, Merzel TK, Lotan A, and Lerer B
- Subjects
- Adaptor Proteins, Vesicular Transport, Animals, Behavior, Animal, Chronic Disease, Disease Models, Animal, Female, Genetic Predisposition to Disease, Magnetic Resonance Imaging, Male, Mice, Mice, Inbred C57BL, Mice, Knockout, Neurogenesis, Stress, Psychological physiopathology, Anxiety physiopathology, Brain physiopathology, Proto-Oncogene Proteins genetics, Stress, Psychological genetics
- Abstract
The Abelson helper integration site 1 (Ahi1) gene plays a pivotal role in brain development and is associated with genetic susceptibility to schizophrenia, and other neuropsychiatric disorders. Translational research in genetically modified mice may reveal the neurobiological mechanisms of such associations. Previous studies of mice heterozygous for Ahi1 knockout (Ahi1+/-) revealed an attenuated anxiety response on various relevant paradigms, in the context of a normal glucocorticoid response to caffeine and pentylenetetrazole. Resting-state fMRI showed decreased amygdalar connectivity with various limbic brain regions and altered network topology. However, it was not clear from previous studies whether stress-hyporesponsiveness reflected resilience or, conversely, a cognitive-emotional deficit. The present studies were designed to investigate the response of Ahi1+/- mice to chronic unpredictable stress (CUS) applied over 9 weeks. Wild type (Ahi1+/+) mice were significantly affected by CUS, manifesting decreased sucrose preference (p < 0.05); reduced anxiety on the elevated plus maze and light dark box and decreased thigmotaxis in the open field (p < 0.01 0.05); decreased hyperthermic response to acute stress (p < 0.05); attenuated contextual fear conditioning (p < 0.01) and increased neurogenesis (p < 0.05). In contrast, Ahi1+/- mice were indifferent to the effects of CUS assessed with the same parameters. Our findings suggest that Ahi1 under-expression during neurodevelopment, as manifested by Ahi1+/- mice, renders these mice stress hyporesponsive. Ahi1 deficiency during development may attenuate the perception and/or integration of environmental stressors as a result of impaired corticolimbic connectivity or aberrant functional wiring. These neural mechanisms may provide initial clues as to the role Ahi1 in schizophrenia and other neuropsychiatric disorders.
- Published
- 2018
- Full Text
- View/download PDF
30. Reduction in endogenous cardiac steroids protects the brain from oxidative stress in a mouse model of mania induced by amphetamine.
- Author
-
Hodes A, Lifschytz T, Rosen H, Cohen Ben-Ami H, and Lichtstein D
- Subjects
- Amphetamine-Related Disorders drug therapy, Amphetamine-Related Disorders metabolism, Animals, Antibodies administration & dosage, Antioxidants pharmacology, Bipolar Disorder metabolism, Brain metabolism, Disease Models, Animal, Male, Mice, Inbred BALB C, Motor Activity drug effects, Motor Activity physiology, Ouabain immunology, Oxidative Stress drug effects, Oxidative Stress physiology, Random Allocation, Amphetamine toxicity, Bipolar Disorder chemically induced, Brain drug effects, Central Nervous System Stimulants toxicity, Neuroprotective Agents pharmacology, Ouabain antagonists & inhibitors
- Abstract
Objectives: Bipolar disorder (BD) is a severe mental illness characterized by episodes of mania and depression. Numerous studies have implicated the involvement of endogenous cardiac steroids (CS), and their receptor, Na
+ , K+ -ATPase, in BD. The aim of the present study was to examine the role of brain oxidative stress in the CS-induced behavioral effects in mice., Methods: Amphetamine (AMPH)-induced hyperactivity, assessed in the open-field test, served as a model for manic-like behavior in mice. A reduction in brain CS was obtained by specific and sensitive anti-ouabain antibodies. The level of oxidative stress was tested in the hippocampus and frontal cortex by measuring the activity of antioxidant enzymes superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPx), as well as the levels of antioxidant non-protein thiols (NPSH) and oxidative damage biomarkers thiobarbituric acid reactive substances (TBARS) and protein carbonyl (PC)., Results: AMPH administration resulted in a marked hyperactivity and increased oxidative stress, as manifested by increased SOD activity, decreased activities of CAT and GPx, reduced levels of NPSH and increased levels of TBARS and PC. The administration of anti-ouabain antibodies, which reduced the AMPH-induced hyperactivity, protected against the concomitant oxidative stress in the brain., Conclusions: Our results demonstrate that oxidative stress participates in the effects of endogenous CS on manic-like behavior induced by AMPH. These finding support the notion that CS and oxidative stress may be associated with the pathophysiology of mania and BD., (Copyright © 2018 Elsevier Inc. All rights reserved.)- Published
- 2018
- Full Text
- View/download PDF
31. Differentially Severe Cognitive Effects of Compromised Cerebral Blood Flow in Aged Mice: Association with Myelin Degradation and Microglia Activation.
- Author
-
Wolf G, Lotan A, Lifschytz T, Ben-Ari H, Kreisel Merzel T, Tatarskyy P, Valitzky M, Mernick B, Avidan E, Koroukhov N, and Lerer B
- Abstract
Bilateral common carotid artery stenosis (BCAS) models the effects of compromised cerebral blood flow on brain structure and function in mice. We compared the effects of BCAS in aged (21 month) and young adult (3 month) female mice, anticipating a differentially more severe effect in the older mice. Four weeks after surgery there was a significant age by time by treatment interaction on the radial-arm water maze (RAWM; p = 0.014): on the first day of the test, latencies of old mice were longer compared to the latencies of young adult mice, independent of BCAS. However, on the second day of the test, latencies of old BCAS mice were significantly longer than old control mice ( p = 0.049), while latencies of old controls were similar to those of the young adult mice, indicating more severe impairment of hippocampal dependent learning and working memory by BCAS in the older mice. Fluorescence staining of myelin basic protein (MBP) showed that old age and BCAS both induced a significant decrease in fluorescence intensity. Evaluation of the number oligodendrocyte precursor cells demonstrated augmented myelin replacement in old BCAS mice ( p < 0.05) compared with young adult BCAS and old control mice. While microglia morphology was assessed as normal in young adult control and young adult BCAS mice, microglia of old BCAS mice exhibited striking activation in the area of degraded myelin compared to young adult BCAS ( p < 0.01) and old control mice ( p < 0.05). These findings show a differentially more severe effect of cerebral hypoperfusion on cognitive function, myelin integrity and inflammatory processes in aged mice. Hypoperfusion may exacerbate degradation initiated by aging, which may induce more severe neuronal and cognitive phenotypes.
- Published
- 2017
- Full Text
- View/download PDF
32. Endogenous cardiac steroids in animal models of mania.
- Author
-
Hodes A, Rosen H, Deutsch J, Lifschytz T, Einat H, and Lichtstein D
- Subjects
- Animals, Antibodies pharmacology, Bipolar Disorder therapy, Disease Models, Animal, Enzyme-Linked Immunosorbent Assay methods, Mice, Phosphorylation physiology, Behavior, Animal drug effects, Behavior, Animal physiology, Bipolar Disorder metabolism, Frontal Lobe enzymology, Frontal Lobe metabolism, Ouabain immunology
- Abstract
Objectives: Bipolar disorder (BD) is a complex psychiatric disorder characterized by mania and depression. Alterations in brain Na(+) , K(+) -ATPase and cardiac steroids (CSs) have been detected in BD, raising the hypothesis of their involvement in this pathology. The present study investigated the behavioral and biochemical consequences of a reduction in endogenous brain CS activity in animal models of mania., Methods: Amphetamine (AMPH)-induced hyperactivity in BALB/c and black Swiss mice served as a model of mania. Behavior was evaluated in the open-field test in naïve mice or in mice treated with anti-ouabain antibodies. CS levels were determined by enzyme-linked immunosorbent assay (ELISA), using sensitive and specific anti-ouabain antibodies. Extracellular signal-regulated kinase (ERK) and protein kinase B (Akt) phosphorylation levels in the frontal cortex were determined by western blot analysis., Results: Administration of AMPH to BALB/c and black Swiss mice resulted in a marked increase in locomotor activity, accompanied by a threefold increase in brain CSs. The lowering of brain CSs by the administration of anti-ouabain antibodies prevented the hyperactivity and the increase in brain CS levels. AMPH caused an increase in phosphorylated ERK (p-ERK) and phosphorylated Akt (p-Akt) levels in the frontal cortex, which was significantly reduced by administration of the antibodies. A synthetic 'functional antagonist' of CSs, 4-(3'α-15'β-dihydroxy-5'β-estran-17'β-yl) furan-2-methyl alcohol, also resulted in attenuation of AMPH-induced hyperactivity., Conclusions: These results are in accordance with the notion that malfunctioning of the Na(+) , K(+) -ATPase/CS system may be involved in the manifestation of mania and identify this system as a potential new target for drug development., (© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2016
- Full Text
- View/download PDF
33. Effectiveness of Aerobic Exercise as an Augmentation Therapy for Inpatients with Major Depressive Disorder: A Preliminary Randomized Controlled Trial.
- Author
-
Shachar-Malach T, Cooper Kazaz R, Constantini N, Lifschytz T, and Lerer B
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Combined Modality Therapy, Depressive Disorder, Major drug therapy, Exercise, Female, Humans, Male, Middle Aged, Treatment Outcome, Young Adult, Antidepressive Agents therapeutic use, Depressive Disorder, Major therapy, Exercise Therapy methods
- Abstract
Background: Physical exercise has been shown to reduce depressive symptoms when used in combination with antidepressant medication. We report a randomized controlled trial of aerobic exercise compared to stretching as an augmentation strategy for hospitalized patients with major depression., Methods: Male or female patients, 18-80 years, diagnosed with a Major Depressive Episode, were randomly assigned to three weeks of augmentation therapy with aerobic (n=6) or stretching exercise (n=6). Depression was rated, at several time points using the 21-item Hamilton Depression Scale (HAM-D), Beck Depression Inventory (BDI) and other scales., Results: According to the HAM-D, there were four (out of six) responders in the aerobic group, two of whom achieved remission, and none in the stretching group. According to the BDI, there were two responders in the aerobic group who were also remitters and none in the stretching group., Conclusions: The results of this small study suggest that aerobic exercise significantly improves treatment outcome when added to antidepressant medication. However, due to the small sample size the results must be regarded as preliminary and further studies are needed to confirm the findings.
- Published
- 2015
34. Do tardive dyskinesia and L-dopa induced dyskinesia share common genetic risk factors? An exploratory study.
- Author
-
Greenbaum L, Goldwurm S, Zozulinsky P, Lifschytz T, Cohen OS, Yahalom G, Cilia R, Tesei S, Asselta R, Inzelberg R, Kohn Y, Hassin-Baer S, and Lerer B
- Subjects
- Aged, Case-Control Studies, Dyskinesia, Drug-Induced ethnology, Female, Humans, Israel, Italy, Jews, Levodopa adverse effects, Male, Middle Aged, Dyskinesia, Drug-Induced genetics, Genetic Predisposition to Disease, Polymorphism, Single Nucleotide
- Abstract
Tardive dyskinesia (TD) in schizophrenia patients treated with antipsychotic medications and L-dopa induced dyskinesia (LID) among Parkinson's disease (PD) affected individuals share similar clinical features. Both conditions are induced by chronic exposure to drugs that target dopaminergic receptors (antagonists in TD and agonists in LID) and cause pulsatile and nonphysiological stimulation of these receptors. We hypothesized that the two motor adverse effects partially share genetic risk factors such that certain genetic variants exert a pleiotropic effect, influencing susceptibility to TD as well as to LID. In this pilot study, we focused on 21 TD-associated SNPs, previously reported in TD genome-wide association studies or in candidate gene studies. By applying logistic regression and controlling for relevant clinical risk factors, we studied the association of the SNPs with LID vulnerability in two independent pharmacogenetic samples. We included a Jewish Israeli sample of 203 PD patients treated with L-dopa for a minimum of 3 years and evaluated the existence or absence of LID (LID+ = 128; LID- = 75). An Italian sample was composed of early LID developers (within the first 3 years of treatment, N = 187) contrasted with non-early LID developers (after 7 years or more of treatment, N = 203). None of the studied SNPs were significantly associated with LID susceptibility in the two samples. Therefore, we were unable to obtain proof of concept for our initial hypothesis of an overlapping contribution of genetic risk factors to TD and LID. Further studies in larger samples are required to reach definitive conclusions.
- Published
- 2013
- Full Text
- View/download PDF
35. Relationship between Rgs2 gene expression level and anxiety and depression-like behaviour in a mutant mouse model: serotonergic involvement.
- Author
-
Lifschytz T, Broner EC, Zozulinsky P, Slonimsky A, Eitan R, Greenbaum L, and Lerer B
- Subjects
- 8-Hydroxy-2-(di-n-propylamino)tetralin pharmacology, Analysis of Variance, Animals, Brain Chemistry genetics, Feeding Behavior drug effects, Female, Genotype, Male, Mice, Mice, Inbred C57BL, Mutation genetics, Mutation physiology, Real-Time Polymerase Chain Reaction, Serotonin Receptor Agonists pharmacology, Social Behavior, Social Environment, Swimming psychology, Anxiety genetics, Anxiety psychology, Depression genetics, Depression psychology, Gene Expression physiology, RGS Proteins genetics, Serotonin physiology
- Abstract
RGS2 is a member of a family of proteins that negatively modulate G-protein coupled receptor transmission. Variations in the RGS2 gene were found to be associated in humans with anxious and depressive phenotypes. We sought to study the relationship of Rgs2 expression level to depression and anxiety-like behavioural features, sociability and brain 5-HT1A and 5-HT1B receptor expression. We studied male mice carrying a mutation that causes lower Rgs2 gene expression, employing mice heterozygous (Het) or homozygous (Hom) for this mutation, or wild-type (WT). Mice were subjected to behavioural tests reflecting depressive-like behaviour [forced swim test (FST), novelty suppressed feeding test (NSFT)], elevated plus maze (EPM) for evaluation of anxiety levels and the three-chamber sociability test. The possible involvement of raphe nucleus 5-HT1A receptors in these behavioural features was examined by 8-OH-DPAT-induced hypothermia. Expression levels of 5-HT1A and 5-HT1B receptors in the cortex, raphe nucleus and hypothalamus were compared among mice of the different Rgs2 genotype groups. NSFT results demonstrated that Hom mice showed more depressive-like features than Rgs2 Het and WT mice. A trend for such a relationship was also suggested by the FST results. EPM and sociability test results showed Hom and Het mice to be more anxious and less sociable than WT mice. In addition Hom and Het mice were characterized by lower basal body temperature and demonstrated less 8-OH-DPAT-induced hypothermia than WT mice. Finally, Hom and Het mice had significantly lower 5-HT1A and 5-HT1B receptor expression levels in the raphe than WT mice. Our findings demonstrate a relationship between Rgs2 gene expression level and a propensity for anxious and depressive-like behaviour and reduced social interaction that may involve changes in serotonergic receptor expression.
- Published
- 2012
- Full Text
- View/download PDF
36. Alteration in RGS2 expression level is associated with changes in haloperidol induced extrapyramidal features in a mutant mouse model.
- Author
-
Greenbaum L, Lifschytz T, Zozulinsky P, Broner EC, Slonimsky A, Kohn Y, and Lerer B
- Subjects
- Animals, Basal Ganglia Diseases psychology, Female, Haloperidol pharmacology, Male, Mice, Mice, Inbred C57BL, Mice, Transgenic, Basal Ganglia Diseases chemically induced, Basal Ganglia Diseases metabolism, Disease Models, Animal, Gene Expression Regulation drug effects, Haloperidol toxicity, RGS Proteins biosynthesis
- Abstract
Antipsychotic induced Parkinsonism (AIP) is a common adverse effect of antipsychotic drug treatment among schizophrenia patients. Two previous studies showed association of the rs4606 SNP in the 3' untranslated region of the regulator of G protein signaling 2 gene (RGS2) with susceptibility to AIP. Since rs4606 reportedly influences expression of RGS2, we applied a translational approach and studied the effect of chronic (24 days) exposure to haloperidol on AIP-like features in mice carrying a mutation that causes lower Rgs2 gene expression. Haloperidol and vehicle treated male mice heterozygous (HET) or homozygous (HOM) for the mutation, or wild type (WT), were evaluated for open field locomotion, catalepsy duration, pole test performance and rota-rod latency to fall. We showed that in haloperidol treated mice lower Rgs2 expression is associated with better performance on the open field, catalepsy and rota-rod tests but not the pole test. Results were most consistent for the 0.2 mg/kg/d haloperidol dose. These observations support the possible involvement of RGS2 in mechanisms underlying susceptibility to AIP., (Copyright © 2011 Elsevier B.V. and ECNP. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
37. Association of the ZFPM2 gene with antipsychotic-induced parkinsonism in schizophrenia patients.
- Author
-
Greenbaum L, Smith RC, Lorberboym M, Alkelai A, Zozulinsky P, Lifschytz T, Kohn Y, Djaldetti R, and Lerer B
- Subjects
- Adult, Antipsychotic Agents therapeutic use, Corpus Striatum metabolism, Cross-Sectional Studies, Female, Genome-Wide Association Study, Humans, Israel, Jews, Logistic Models, Male, Middle Aged, Parkinson Disease physiopathology, Parkinson Disease, Secondary physiopathology, Polymorphism, Single Nucleotide, Severity of Illness Index, Substantia Nigra metabolism, Tomography, Emission-Computed, Single-Photon, United States, Antipsychotic Agents adverse effects, DNA-Binding Proteins genetics, Parkinson Disease, Secondary chemically induced, Schizophrenia drug therapy, Transcription Factors genetics
- Abstract
Rationale: Antipsychotic-induced parkinsonism (AIP) is a severe adverse affect of antipsychotic drug treatment. Recently, our group performed a genome-wide association study (GWAS) for AIP severity, and identified several potential AIP risk variants., Objectives: The aim of this study was to validate our original AIP-GWAS susceptibility variants and to understand their possible function., Methods: We conducted a validation study of 15 single-nucleotide polymorphisms (SNPs) in an independent sample of 178 US schizophrenia patients treated for at least a month with typical or atypical antipsychotics. Then, a sample of 49 Jewish Israeli Parkinson's disease (PD) patients with available neuroimaging ([(123)I]-FP-CIT-SPECT) data was analyzed, to study association of confirmed AIP SNPs with level of dopaminergic deficits in the putamen., Results: Using logistic regression and controlling for possible confounders, we found nominal association of the intronic SNP, rs12678719, in the Zinc Finger Protein Multitype 2 (ZFPM2) gene with AIP (62 affected/116 unaffected), in the whole sample (p = 0.009; P = 5.97 × 10(-5) in the GWAS), and in the African American sub-sample (N = 111; p = 0.002). The same rs12678719-G AIP susceptibility allele was associated with lower levels of dopaminergic neuron related ligand binding in the contralateral putamen of PD patients (p = 0.026)., Conclusions: Our preliminary findings support association of the ZFPM2 SNP, rs12678719, with AIP. At the functional level, this variant is associated with deficits in the nigrostriatal pathway in PD patients that may be related to latent subclinical deficits among AIP-prone individuals with schizophrenia. Further validation studies in additional populations are required.
- Published
- 2012
- Full Text
- View/download PDF
38. The thyroid hormone, triiodothyronine, enhances fluoxetine-induced neurogenesis in rats: possible role in antidepressant-augmenting properties.
- Author
-
Eitan R, Landshut G, Lifschytz T, Einstein O, Ben-Hur T, and Lerer B
- Subjects
- Animals, Depression drug therapy, Depression pathology, Depression psychology, Doublecortin Protein, Drug Synergism, Drug Therapy, Combination, Feeding Behavior drug effects, Feeding Behavior physiology, Hippocampus cytology, Hippocampus drug effects, Male, Rats, Thyroid Hormones administration & dosage, Thyroid Hormones physiology, Triiodothyronine administration & dosage, Antidepressive Agents administration & dosage, Fluoxetine administration & dosage, Neurogenesis drug effects, Neurogenesis physiology, Triiodothyronine physiology
- Abstract
The thyroid hormone triiodothyronine (T3) may accelerate and augment the action of antidepressants. Antidepressants up-regulate neurogenesis in adult rodent hippocampus. We studied the effect of T3 and T3+fluoxetine in enhancement of hippocampal neurogenesis beyond that induced by fluoxetine alone and the correlation with antidepressant behaviour in the novelty suppressed feeding test (NSFT). Rats were administered fluoxetine (5 mg/kg.d), T3 (50 mug/kg.d), fluoxetine (5 mg/kg.d)+T3 (50 mug/kg.d) or saline, for 21 d. Neurogenesis was studied by doublecortin (DCX) immunohistochemistry in the subgranular zone (SGZ) of the hippocampus and the subventricular zone (SVZ). In the NSFT, latency to feeding in animals deprived of food was measured. Fluoxetine and fluoxetine+T3 increased the number of doublecortin-positive (DCX+) cells in the SGZ compared to saline (p=0.00005, p=0.008, respectively). There was a trend towards an increased number of DCX+ cells by T3 compared to saline (p=0.06). Combined treatment with fluoxetine+T3 further increased the number of DCX+ cells compared to T3 or fluoxetine alone (p=0.001, p=0.014, respectively). There was no effect of any of the treatments on number of DCX+ cells in the SVZ. In the NSFT, all treatments (T3, fluoxetine+T3 and fluoxetine) reduced latency to feeding compared to saline (p=0.0004, p=0.00001, p=0.00009, respectively). Fluoxetine+T3 further reduced latency to feeding compared to T3 alone (p=0.05). The results suggest that enhancement of antidepressant action by T3 may be related to its effect of increasing hippocampal neurogenesis and that the antidepressant effect of these treatments is specific to the hippocampus and does not represent a general effect on cell proliferation.
- Published
- 2010
- Full Text
- View/download PDF
39. Effect of triiodothyronine on 5-HT1A and 5-HT1B receptor expression in rat forebrain and on latency to feed in the novelty suppressed feeding test.
- Author
-
Lifschytz T, Goltser-Dubner T, Landshut G, and Lerer B
- Subjects
- Analysis of Variance, Animals, Fluoxetine pharmacology, Male, RNA, Messenger genetics, RNA, Messenger metabolism, Rats, Receptor, Serotonin, 5-HT1A genetics, Receptor, Serotonin, 5-HT1B genetics, Reverse Transcriptase Polymerase Chain Reaction, Selective Serotonin Reuptake Inhibitors pharmacology, Feeding Behavior drug effects, Prosencephalon drug effects, Prosencephalon metabolism, Receptor, Serotonin, 5-HT1A metabolism, Receptor, Serotonin, 5-HT1B metabolism, Triiodothyronine pharmacology
- Abstract
Thyroid hormones, particularly triiodothyronine (T3), have long been used for the treatment of depression, most frequently to enhance the therapeutic activity of other antidepressants. The purpose of this study was to evaluate possible underlying mechanisms for the antidepressant activity of T3. The effects of T3 20 microg/kg/d S.C. and fluoxetine 5mg/kg/d I.P. given alone or in combination for 7 days on the transcription rates of inhibitory serotonergic receptors (5-HT1A and 5-HT1B) were studied in different brain areas of male Sabra rats using real-time PCR. Significant effects of fluoxetine were found on the expression of 5-HT1B receptors in the frontal cortex and of T3 on the expression of 5-HT1A receptors in the amygdala and hippocampus and 5-HT1B receptors in the frontal and entorhinal cortices, the expression being reduced in all cases. An effect of the combination of T3 plus fluoxetine to reduce transcription was observed for 5-HT1A receptors, in the amygdala and dentate gyrus and for 5-HT1B receptors in the entorhinal cortex and anterior raphe nucleus. In the second experiment, the novelty suppressed feeding test (NFST) was used to examine the effects of fluoxetine 5mg/kg/d I.P. and T3 20 or 50 microg/kg/d, alone or in combination for 12 days, on latency to feed. Only the combinations of T3 (20 or 50 microg/kg/d) and fluoxetine (5mg/kg/d) yielded significant behavioral effects in this test. The results of our studies suggest that the mechanism underlying the antidepressant effect of T3 may involve a reduction in 5-HT1A and 5-HT1B receptor transcription rates., (Copyright 2010 Elsevier Inc. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF
40. Sex-dependent effects of fluoxetine and triiodothyronine in the forced swim test in rats.
- Author
-
Lifschytz T, Shalom G, Lerer B, and Newman ME
- Subjects
- Animals, Female, Male, Motor Activity drug effects, Rats, Rats, Wistar, Sex Characteristics, Antidepressive Agents, Second-Generation therapeutic use, Depression prevention & control, Depression psychology, Fluoxetine therapeutic use, Swimming psychology, Triiodothyronine pharmacology
- Abstract
The effects of triiodothyronine (T3) and fluoxetine, administered separately and combined, on behavior of male and female rats in the forced swim test, a procedure for screening antidepressant-like activity, were determined. There were no consistent effects of low doses of fluoxetine (5 mg/kg) or T3 (20 microg/kg), administered daily for 2 weeks. Fluoxetine administered daily at 10 mg/kg for 7 days reduced immobility and increased active behaviors in male rats, but had no effects in female rats. The effects of fluoxetine in male rats were not potentiated by T3. In female rats, T3 at 100 microg/kg given daily for 7 days decreased immobility and increased swimming when these were measured 72 h after the last injection, but not when measurements were performed at an earlier time point. These results provide some support from an animal model for the efficacy of T3 as antidepressant therapy in female patients, but do not provide support for the augmentation and acceleration effects seen clinically when T3 is used in conjunction with established antidepressants such as fluoxetine.
- Published
- 2006
- Full Text
- View/download PDF
41. Basic mechanisms of augmentation of antidepressant effects with thyroid hormone.
- Author
-
Lifschytz T, Segman R, Shalom G, Lerer B, Gur E, Golzer T, and Newman ME
- Subjects
- Animals, Drug Synergism, Drug Therapy, Combination, Humans, Microdialysis, Receptors, Serotonin genetics, Transcription, Genetic, Antidepressive Agents administration & dosage, Antidepressive Agents pharmacology, Antidepressive Agents therapeutic use, Depression drug therapy, Receptors, Serotonin biosynthesis, Selective Serotonin Reuptake Inhibitors administration & dosage, Selective Serotonin Reuptake Inhibitors pharmacology, Selective Serotonin Reuptake Inhibitors therapeutic use, Triiodothyronine administration & dosage, Triiodothyronine pharmacology, Triiodothyronine therapeutic use
- Abstract
The thyroid hormone triiodothyronine (T3) has been used both to augment and accelerate the clinical effects of antidepressants, particularly the tricyclics. More recent work indicates that it may have similar actions with regard to the SSRIs. Two main mechanisms have been put forward to explain its antidepressant actions, (a) an action at the nuclear level involving stimulation of gene transcription, (b) an action at the cell membrane level involving potentiation of neurotransmission. In particular, there is considerable evidence for potentiation by T3 of the actions of the neurotransmitter 5-HT or serotonin. This evidence, which is mainly based on in vivo microdialysis studies, is reviewed, and evidence based on human and animal neuroendocrine studies considered. The effects of T3, alone and together with the SSRI fluoxetine, on mRNA levels for the 5-HT1A and 5-HT1B autoreceptors, which mediate serotonergic neurotransmission by feedback actions at the levels of cell firing(somatodendritic 5-HT1A autoreceptors) and neurotransmitter release (nerve terminal 5-HT1B autoreceptors) were also determined. Administration of a combination of fluoxetine and T3 induced reductions in the transcription of these autoreceptors, which may explain the clinical potentiating effects of this combination, and thus link the nuclear and neurotransmitter hypotheses of T3 action.
- Published
- 2006
- Full Text
- View/download PDF
42. Effects of triiodothyronine and fluoxetine on 5-HT1A and 5-HT1B autoreceptor activity in rat brain: regional differences.
- Author
-
Lifschytz T, Gur E, Lerer B, and Newman ME
- Subjects
- 8-Hydroxy-2-(di-n-propylamino)tetralin pharmacology, Animals, Autoreceptors metabolism, Brain metabolism, Brain Chemistry drug effects, Brain Chemistry physiology, Depressive Disorder drug therapy, Depressive Disorder metabolism, Depressive Disorder physiopathology, Down-Regulation drug effects, Down-Regulation physiology, Drug Synergism, Drug Therapy, Combination, Hypothalamus drug effects, Hypothalamus metabolism, Male, Microdialysis instrumentation, Microdialysis methods, Neurochemistry instrumentation, Neurochemistry methods, Prefrontal Cortex drug effects, Prefrontal Cortex metabolism, Rats, Rats, Wistar, Receptor, Serotonin, 5-HT1A metabolism, Receptor, Serotonin, 5-HT1B metabolism, Serotonin metabolism, Selective Serotonin Reuptake Inhibitors pharmacology, Triiodothyronine metabolism, Autoreceptors drug effects, Brain drug effects, Fluoxetine pharmacology, Receptor, Serotonin, 5-HT1A drug effects, Receptor, Serotonin, 5-HT1B drug effects, Triiodothyronine pharmacology
- Abstract
The thyroid hormone triiodothyronine (T3) augments and accelerates the effects of antidepressant drugs. Although the majority of studies showing this have used tricyclics, a few studies have shown similar effects with the selective serotonin re-uptake inhibitor (SSRI) fluoxetine. In this study we investigated the effects of fluoxetine (5 mg/kg), T3 (20 microg/kg) and the combination of these drugs, each administered daily for 7 days, on serotonergic function in the rat brain, using in vivo microdialysis. Fluoxetine alone induced a trend towards desensitization of 5-HT1A autoreceptors as shown by a reduction in the effect of 8-OH-DPAT to lower 5-HT levels in frontal cortex, and desensitized 5-HT1B autoreceptors in frontal cortex. The combination of fluoxetine and T3 induced desensitization of 5-HT1B autoreceptors in hypothalamus. Since there is evidence linking hypothalamic function and depression, we suggest that this effect may partly account for the therapeutic efficacy of the combination of an SSRI and T3.
- Published
- 2004
- Full Text
- View/download PDF
43. Effects of triiodothyronine on 5-HT(1A) and 5-HT(1B) autoreceptor activity, and postsynaptic 5-HT(1A) receptor activity, in rat hypothalamus: lack of interaction with imipramine.
- Author
-
Gur E, Lifschytz T, Van De Kar LD, Lerer B, and Newman ME
- Subjects
- 8-Hydroxy-2-(di-n-propylamino)tetralin pharmacology, Adrenocorticotropic Hormone metabolism, Analysis of Variance, Animals, Autoreceptors metabolism, Corticosterone metabolism, Drug Interactions, Hypothalamus metabolism, Male, Microdialysis, Microinjections, Rats, Rats, Inbred Strains, Receptor, Serotonin, 5-HT1A metabolism, Receptor, Serotonin, 5-HT1B metabolism, Serotonin Receptor Agonists pharmacology, Synaptic Transmission drug effects, Triiodothyronine administration & dosage, Antidepressive Agents, Tricyclic pharmacology, Autoreceptors drug effects, Hypothalamus drug effects, Imipramine pharmacology, Receptor, Serotonin, 5-HT1A drug effects, Receptor, Serotonin, 5-HT1B drug effects, Triiodothyronine physiology
- Abstract
Triiodothyronine (T3) is effective in both augmenting and accelerating the therapeutic response to antidepressant drugs, especially tricyclics, and there is evidence from both human and animal studies that it acts on serotonergic neurotransmission. In this work we examined the effects of T3 alone and together with imipramine on 5-HT levels in the hypothalamus and on 5-HT(1A) and 5-HT(1B) autoreceptor sensitivity, using in vivo microdialysis in the rat. The effects of T3 on postsynaptic 5-HT(1A) receptor activity in the hypothalamus were also determined using a neuroendocrine challenge procedure. T3 administered daily at 20 microg/kg s.c. for 2 weeks reduced the sensitivity of 5-HT(1A) autoreceptors which control 5-HT release, as measured by the effect of 8-OH-DPAT to decrease 5-HT in the hypothalamus, and also the sensitivity of hypothalamic 5-HT(1B) receptors as measured by the effect of the 5-HT(1B) receptor agonist CP 93129 to decrease 5-HT release. Imipramine at 10 mg/kg daily for 4 weeks by osmotic minipump reduced 5-HT(1A) autoreceptor activity, as measured by the effect of 8-OH-DPAT in the hypothalamus, but the combination of T3 and imipramine given for 2 weeks did not affect either 5-HT(1A) or 5-HT(1B) autoreceptor activity. T3 at 20 microg/kg s.c. given daily for 1 week also reduced the sensitivity of postsynaptic 5-HT(1A) receptors in the hypothalamus, as measured by injection of 8-OH-DPAT and determination of the plasma ACTH and corticosterone responses. Animals which received T3 for 7 days showed a dose-dependent reduction in plasma free T4 levels but no change in total T3 levels. We conclude that while T3 alone affects both presynaptic and postsynaptic components of the serotonergic system, these effects may not be responsible for the therapeutic acceleration action seen with a combination of a tricyclic drug and T3.
- Published
- 2004
- Full Text
- View/download PDF
44. Effects of triiodothyronine and imipramine on basal 5-HT levels and 5-HT(1) autoreceptor activity in rat cortex.
- Author
-
Gur E, Lifschytz T, Lerer B, and Newman ME
- Subjects
- 8-Hydroxy-2-(di-n-propylamino)tetralin pharmacology, Animals, Autoreceptors physiology, Cerebral Cortex metabolism, Dose-Response Relationship, Drug, Drug Synergism, Male, Rats, Receptor, Serotonin, 5-HT1B, Receptors, Serotonin physiology, Receptors, Serotonin, 5-HT1, Serotonin Receptor Agonists pharmacology, Antidepressive Agents, Tricyclic pharmacology, Autoreceptors drug effects, Cerebral Cortex drug effects, Imipramine pharmacology, Receptors, Serotonin drug effects, Serotonin metabolism, Triiodothyronine pharmacology
- Abstract
Clinical studies have shown that triiodothyronine (T3) both augments and accelerates the therapeutic response to antidepressant drugs, particularly tricyclics. There is evidence that this effect is mediated by the serotonergic system. We show here that T3 administered daily for 7 days over the range 0.02-0.5 mg/kg increases basal serotonin (5-hydroxytryptamine, 5-HT) levels, as measured by in vivo microdialysis in rat cortex, in a dose-dependent fashion. All the doses of T3 examined reduced 5-HT(1A) autoreceptor activity, as measured by the effect of 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT, 0.05 mg/kg s.c.) to decrease 5-HT levels in frontal cortex. T3 administered daily for 14 days at 0.02 mg/kg also reduced 5-HT(1B) autoreceptor activity, as measured by the effect of locally administered 3-(1,2,5,6-tetrahydropyrid-4-yl)pyrrolo[3,2-b]pyrid-5-one (CP 93129, 10 microM) to decrease 5-HT levels. In animals administered imipramine (10 mg/kg/day by osmotic minipump) concurrently with T3 injections, no further changes in either 5-HT(1A) or 5-HT(1B) autoreceptor activity were seen. We suggest that the effect of T3 to accelerate the therapeutic actions of antidepressant drugs may be due to a combination of the actions of T3 at autoreceptors and the actions of the drugs at postsynaptic 5-HT(1A) receptors.
- Published
- 2002
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.